Hypocretin (orexin) cell loss in Parkinson's disease.

Hypocretin (orexin) cell loss in Parkinson's disease. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Hypocretin (orexin) cell loss in Parkinson's disease. Abstract Text:

Thomas C Thannickal,Yuan-Yang Lai,Jerome M Siegel,

It has recently been reported that Parkinson's disease (PD) is preceded and accompanied by daytime sleep attacks, nocturnal insomnia, REM sleep behaviour disorder, hallucinations and depression, symptoms which are frequently as troublesome as the motor symptoms of PD. All these symptoms are present in narcolepsy, which is linked to a selective loss of hypocretin (Hcrt) neurons. In this study, the Hcrt system was examined to determine if Hcrt cells are damaged in PD. The hypothalamus of 11 PD (mean age 79 +/- 4) and 5 normal (mean age 77 +/- 3) brains was examined. Sections were immunostained for Hcrt-1, melanin concentrating hormone (MCH) and alpha synuclein and glial fibrillary acidic protein (GFAP). The substantia nigra of 10 PD brains and 7 normal brains were used for a study of neuromelanin pigmented cell loss. The severity of PD was assessed using the Hoehn and Yahr scale and the level of neuropathology was assessed using the Braak staging criteria. Cell number, distribution and size were determined with stereologic techniques on a one in eight series. We found an increasing loss of hypocretin cells with disease progression. Similarly, there was an increased loss of MCH cells with disease severity. Hcrt and MCH cells were lost throughout the anterior to posterior extent of their hypothalamic distributions. The percentage loss of Hcrt cells was minimal in stage I (23%) and was maximal in stage V (62%). Similarly, the percentage loss of MCH cells was lowest in stage I (12%) and was highest in stage V (74%). There was a significant increase (P = 0.0006, t = 4.25, df = 15) in the size of neuromelanin containing cells in PD patients, but no difference in the size of surviving Hcrt (P = 0.18, t = 1.39, df = 14) and MCH (P = 0.28, t = 1.39, df = 14) cells relative to controls. In summary, we found that PD is characterized by a massive loss of Hcrt neurons. Thus, the loss of Hcrt cells may be a cause of the narcolepsy-like symptoms of PD and may be ameliorated by treatments aimed at reversing the Hcrt deficit. We also saw a substantial loss of hypothalamic MCH neurons. The losses of Hcrt and MCH neurons are significantly correlated with the clinical stage of PD, not disease duration, whereas the loss of neuromelanin cells is significantly correlated only with disease duration. The significant correlations that we found between the loss of Hcrt and MCH neurons and the clinical stage of PD, in contrast to the lack of a relationship of similar strength between loss of neuromelanin containing cells and the clinical symptoms of PD, suggests a previously unappreciated relationship between hypothalamic dysfunction and the time course of the overall clinical picture of PD.

Hypocretin (orexin) cell loss in Parkinson's disease. Publishing Authors By Initials

TC Thannickal,YY Lai,JM Siegel,

For similar proteins: nerve tissue proteins: synucleins: alpha-synuclein research abstracts see: proteins: nerve tissue proteins: synucleins: alpha-synuclein research

PUBMED ID PMID:

MEDLINE DATE:

Hypocretin (orexin) cell loss in Parkinson's disease. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Brain : a journal of neurology

VOLUME: 130

Page Numbers: 1586-95

Journal Abbreviation: Brain

ISSN: 1460-2156

DAY: 9

MONTH: 05

YEAR: 2007

Hypocretin (orexin) cell loss in Parkinson's disease. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372537

Hypocretin (orexin) cell loss in Parkinson's disease. Keywords Mesh Terms:

KEYWORDS: alpha-Synuclein

MESH TERMS: analysis

Chemical & Substance for Abstract: Hypocretin (orexin) cell loss in Parkinson's disease. Information

Substance Name: melanin-concentrating hormone

Registry Number: 67382-96-1

Grant and Affiliation Information for Hypocretin (orexin) cell loss in Parkinson's disease.

AFFILIATION: Department of Psychiatry, University of California at Los Angeles, Los Angeles, CA 90095, USA.

Country: England

AGENCY: United States NINDS

GRANT: NS42566

ACRONYM: NS

MEDLINETA: Brain

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Hypocretin orexin cell loss in Parkinson's disease Related Publications

• Anti-TGF-beta2 antibody therapy inhibits postoperative resynostosis in craniosynostotic rabbits.
• Association of PSD-95 with ErbB4 facilitates neuregulin signaling in cerebellar granule neurons in culture.
• At what age can children report dependably on their asthma health status?
• Attentional modulation of receptive field structure in area 7a of the behaving monkey.
• Autoimmunity versus tolerance: can dying cells tip the balance?
• Effect of the ovulatory cycle on oviductal sperm storage in the domestic fowl.
• Effects of glossopharyngeal insufflation on cardiac function: an echocardiographic study in elite breath-hold divers.
• Fighting cancer with fitness: dietary outcomes of a randomized, controlled lifestyle change intervention in healthy African-American women.
• Hypocretin (orexin) cell loss in Parkinson's disease.
• Informatics in radiology: GridCAD: grid-based computer-aided detection system.
• Integration of hydrogels with hard and soft microstructures.
• Large germline deletions and duplication in isolated cerebral cavernous malformation patients.
• MDCT of tracheobronchial narrowing in pediatric patients.
• Mecamylamine blocks nicotine-induced enhancement of the P20 auditory event-related potential and evoked gamma.
• MedlinePlus and the challenge of low health literacy: findings from the Colonias project.
• Mortality partitions and their relevance to research on senescence.
• Onset of puberty in CD-1 mouse pups exposed prenatally through weaning to endophyte-infected tall fescue seed.
• Oxidation of 2-mercaptobenzothiazole in latex gloves and its possible haptenation pathway.
• Phage display-based molecular methods in immunohematology.
• Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits.
• Pneumonitis in human cytomegalovirus infection.
• Postoperative anti-Tgf-beta2 antibody therapy improves intracranial volume and craniofacial growth in craniosynostotic rabbits.
• Premature carotid artery disease in long-term survivors of childhood cancer treated with neck irradiation: a series of 5 cases.
• Reproducibility of platelet function testing.
• Sexual violence inside prisons: rates of victimization.
• Stress and health: psychological, behavioral, and biological determinants.
• The effects of yoga practice on psychological well-being: 2426: board #105 june 1 3:30 PM -5:00 PM.
• The neurobiology of aggression and rage: role of cytokines.
• Trends in the inpatient mental health treatment of children and adolescents in US community hospitals between 1990 and 2000.
• Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer.